GRI Bio, Inc.

GRI Healthcare Biotechnology

In the quarter to June 2026, EPS grew 97.5% and free cash flow grew 54.3%, each against the same quarter a year earlier.

1.38 0.02 −1.43%
Market cap
$3.1M
P/E
0.0×
Fwd P/E
−4.2×
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
1.70 3.25 14.21 10.30
Net Debt/EBITDA
1.21 3.09 5.52 6.64
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(24.71) (30.29) (2.97) (0.80)
Book value per Share
21.29 61.18 8.50 5.70
Free Cash Flow
(2.31) (2.97) (3.68) (1.45)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates